Tehran University of Medical Sciences Iranian Journal of Psychiatry 1735-4587 8 1 2013 03 15 59 60 Kamyar Mollazadeh-Moghaddam Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran AND National Drug and Poison Information Center, Deputy of Food and Drug, Shahid Beheshti University of Medical Sciences, Tehran, Iran AND Milad Clinical Research Center, Milad Hospital, Tehran, Iran. Arsia Jamali Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran AND Milad Clinical Research Center, Milad Hospital, Tehran, Iran. Fatemeh Adili-Aghdam Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. Shahin Akhondzadeh Ph.D., FBPharmacolS. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 1333795914, Iran. 2015 10 14 Donepezil, a member of the acetylcholinesterase inhibitor family, is approved for management of cognitive impairments as well as behavioral complications in patients with neurodegenerative Alzheimer's disease. Generally, donepezil is regarded as a safe medication in patients with Alzheimer's disease although there have been reports of several minor adverse events including gastrointestinal disturbances. Herein we describe a patient with Alzheimer's disease who demonstrated delirious behavior upon treatment with donepezil. https://ijps.tums.ac.ir/index.php/ijps/article/view/192 https://ijps.tums.ac.ir/index.php/ijps/article/download/192/188